These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 20021639

  • 1. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
    Schmidt MK, Tommiska J, Broeks A, van Leeuwen FE, Van't Veer LJ, Pharoah PD, Easton DF, Shah M, Humphreys M, Dörk T, Reincke SA, Fagerholm R, Blomqvist C, Nevanlinna H.
    Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
    [Abstract] [Full Text] [Related]

  • 2. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
    van den Broek AJ, Broeks A, Horlings HM, Canisius SV, Braaf LM, Langerød A, Van't Veer LJ, Schmidt MK.
    Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
    [Abstract] [Full Text] [Related]

  • 3. Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis.
    Cheng H, Ma B, Jiang R, Wang W, Guo H, Shen N, Li D, Zhao Q, Wang R, Yi P, Zhao Y, Liu Z, Huang T.
    Mol Biol Rep; 2012 Sep; 39(9):9265-74. PubMed ID: 22729912
    [Abstract] [Full Text] [Related]

  • 4. MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.
    Okishiro M, Kim SJ, Tsunashima R, Nakayama T, Shimazu K, Shimomura A, Maruyama N, Tamaki Y, Noguchi S.
    Breast Cancer Res Treat; 2012 Apr; 132(3):947-53. PubMed ID: 21706156
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients.
    Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ.
    Int J Cancer; 2007 Feb 01; 120(3):563-5. PubMed ID: 17096342
    [Abstract] [Full Text] [Related]

  • 10. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, Dahiya R.
    Clin Cancer Res; 2007 Jul 15; 13(14):4123-9. PubMed ID: 17634539
    [Abstract] [Full Text] [Related]

  • 11. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
    Idbaih A, Boisselier B, Marie Y, Sanson M, El Hallani S, Crinière E, Fourtassi M, Paris S, Carpentier C, Rousseau A, Mokhtari K, Combadière C, Laigle-Donadey F, Hoang-Xuan K, Delattre JY.
    Brain Res; 2008 Mar 10; 1198():16-20. PubMed ID: 18262501
    [Abstract] [Full Text] [Related]

  • 12. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
    Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH, Chanock SJ, Ambs S.
    J Natl Cancer Inst; 2006 Jul 05; 98(13):911-9. PubMed ID: 16818855
    [Abstract] [Full Text] [Related]

  • 13. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations.
    Fang S, Krahe R, Lozano G, Han Y, Chen W, Post SM, Zhang B, Wilson CD, Bachinski LL, Strong LC, Amos CI.
    PLoS One; 2010 May 26; 5(5):e10813. PubMed ID: 20520810
    [Abstract] [Full Text] [Related]

  • 14. Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome.
    Wu CC, Krahe R, Lozano G, Zhang B, Wilson CD, Jo EJ, Amos CI, Shete S, Strong LC.
    Hum Genet; 2011 Jun 26; 129(6):663-73. PubMed ID: 21305319
    [Abstract] [Full Text] [Related]

  • 15. Association of the MDM2 SNP285 and SNP309 Genetic Variants with the Risk, Age at Onset and Prognosis of Breast Cancer in Central European Women: A Hospital-Based Case-Control Study.
    Miedl H, Lebhard J, Ehart L, Schreiber M.
    Int J Mol Sci; 2019 Jan 25; 20(3):. PubMed ID: 30691044
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
    Ponti F, Corsini S, Gnoli M, Pedrini E, Mordenti M, Sangiorgi L.
    Fam Cancer; 2016 Oct 25; 15(4):635-43. PubMed ID: 26956143
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
    Toffoli G, Biason P, Russo A, De Mattia E, Cecchin E, Hattinger CM, Pasello M, Alberghini M, Ferrari C, Scotlandi K, Picci P, Serra M.
    Clin Cancer Res; 2009 May 15; 15(10):3550-6. PubMed ID: 19451596
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.